<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40232">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02582632</url>
  </required_header>
  <id_info>
    <org_study_id>M15-684</org_study_id>
    <secondary_id>2015-003370-33</secondary_id>
    <nct_id>NCT02582632</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Na誰ve Hepatitis C Virus Genotype 1b-Infected Adults</brief_title>
  <acronym>GARNET</acronym>
  <official_title>An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Na誰ve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of ombitasvir/paritaprevir/ ritonavir and
      dasabuvir administered for 8 weeks in treatment-na誰ve participants with genotype 1b
      hepatitis C virus (HCV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who achieve sustained virologic response 12 weeks post-treatment (SVR12)</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>Hepatitis c virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic failure during treatment</measure>
    <time_frame>Up to 8 weeks while on treatment</time_frame>
    <description>The percentage of participants with confirmed &gt;=1 log10 IU/mL increase from nadir in HCV RNA at any time point during treatment or with confirmed, quantifiable HCV RNA among participants with previous unquantifiable HCV RNA during treatment; or failure to suppress during treatment with at least 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment relapse</measure>
    <time_frame>Up to 12 weeks after last dose of study drug</time_frame>
    <description>The percentage of participants with confirmed, quantifiable HCV RNA among participants with previous unquantifiable HCV RNA at the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of female participants who achieve sustained virologic response 12 (SVR12) weeks post-treatment</measure>
    <time_frame>12 weeks after the last actual dose of study drug</time_frame>
    <description>HCV RNA levels less than the lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with low baseline viral load who achieve sustained virologic response 12 (SVR12) weeks post-treatment</measure>
    <time_frame>Baseline and 12 weeks after the last actual dose of study drug</time_frame>
    <description>HCV RNA levels less than the lower limit of quantification.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Hepatitis C Infection</condition>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/Paritaprevir/Ritonavir(25 mg/150 mg/100 mg once daily) and Dasabuvir (250 mg twice daily) administered for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/Paritaprevir/Ritonavir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir</arm_group_label>
    <other_name>ABT-267/ABT-450/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasabuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir</arm_group_label>
    <other_name>ABT-333</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic HCV infection at Screening.

          2. Screening laboratory result indicating HCV genotype 1b infection.

          3. Treatment-na誰ve and non-cirrhotic.

        Exclusion Criteria:

          1. HCV genotype or subtype other than GT1b.

          2. Positive test result for Hepatitis B surface antigen (HbsAg) or confirmed positive
             anti-HIV antibody (HIV Ab) (test).

          3. Any current or past clinical evidence of cirrhosis.

          4. Screening laboratory analyses that shows abnormal results.

          5. Clinically significant abnormalities or co-morbidities, other than HCV infection that
             make the participant an unsuitable candidate for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Dumas, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145473</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145471</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145472</name>
      <address>
        <city>Woolloongabba, Brisbane</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145475</name>
      <address>
        <city>Toronto</city>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145474</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145477</name>
      <address>
        <city>Winnipeg</city>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145909</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145488</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145487</name>
      <address>
        <city>Marseilles</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145491</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145625</name>
      <address>
        <city>Kiel</city>
        <zip>24146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145347</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145358</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49414 92</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145536</name>
      <address>
        <city>Rome</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145535</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145547</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145548</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145551</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145550</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 145549</name>
      <address>
        <city>Portsmouth, Hampshire</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 1, 2016</lastchanged_date>
  <firstreceived_date>October 20, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Interferon-Free</keyword>
  <keyword>Ribavirin-Free</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C Genotype 1b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
